Education
About Us
Working with TipRanks
Follow Us
Summit Therapeutics PLC (SMMT)
:SMMT
Total Valuation
Summit Therapeutics has a market cap or net worth of $13.27B. The enterprise value is $15.13B.
Market Cap$13.27B
Enterprise Value$15.13B
Share Statistics
Summit Therapeutics has 744,442,570 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding744,442,570
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Summit Therapeutics’s return on equity (ROE) is -0.57 and return on invested capital (ROIC) is 0.08%.
Return on Equity (ROE)-0.57
Return on Assets (ROA)-0.51
Return on Invested Capital (ROIC)0.08%
Return on Capital Employed (ROCE)<0.01
Revenue Per Employee0.00
Profits Per Employee-1.39M
Employee Count159
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Summit Therapeutics is ―. Summit Therapeutics’s PEG ratio is 0.84.
PE Ratio―
PS Ratio0.00
PB Ratio32.99
Price to Fair Value32.99
Price to FCF-90.17
Price to Operating Cash Flow-48.78
PEG Ratio0.84
Income Statement
In the last 12 months, Summit Therapeutics had revenue of 0.00 and earned -221.31M in profits. Earnings per share was -0.31.
Revenue0.00
Gross Profit-15.01M
Operating Income313.00K
Pretax Income-221.31M
Net Income-221.31M
EBITDA-212.85M
Earnings Per Share (EPS)-0.31
Cash Flow
In the last 12 months, operating cash flow was -271.60M and capital expenditures -520.08K, giving a free cash flow of -272.11M billion.
Operating Cash Flow-271.60M
Free Cash Flow-272.11M
Free Cash Flow per Share-0.37
Dividends & Yields
Summit Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.49
52-Week Price Change-4.55%
50-Day Moving Average18.51
200-Day Moving Average21.89
Relative Strength Index (RSI)49.81
Average Volume (3m)2.32M
Important Dates
Summit Therapeutics upcoming earnings date is Mar 12, 2026, After Close (Confirmed).
Last Earnings DateOct 20, 2025
Next Earnings DateMar 12, 2026
Ex-Dividend Date―
Financial Position
Summit Therapeutics as a current ratio of 10.15, with Debt / Equity ratio of 2.82%
Current Ratio10.15
Quick Ratio10.15
Debt to Market Cap0.00
Net Debt to EBITDA0.46
Interest Coverage Ratio0.04
Taxes
In the past 12 months, Summit Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Summit Therapeutics EV to EBITDA ratio is -59.80, with an EV/FCF ratio of -89.48.
EV to Sales0.00
EV to EBITDA-59.80
EV to Free Cash Flow-89.48
EV to Operating Cash Flow-89.57
Balance Sheet
Summit Therapeutics has $238.88M in cash and marketable securities with $5.43M in debt, giving a net cash position of $233.45M billion.
Cash & Marketable Securities$238.88M
Total Debt$5.43M
Net Cash$233.45M
Net Cash Per Share$0.31
Tangible Book Value Per Share$0.54
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Summit Therapeutics is $42.49, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$42.49
Price Target Upside149.35% Upside
Analyst ConsensusModerate Buy
Analyst Count12
Revenue Growth Forecast―
EPS Growth Forecast-348.63%